These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD. Sanfilippo C; Forlenza O; Zetterberg H; Blennow K J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278 [TBL] [Abstract][Full Text] [Related]
31. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive. Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253 [TBL] [Abstract][Full Text] [Related]
32. Changes in cerebrospinal fluid nerve growth factor levels during chick embryonic development. Mashayekhi F; Azari M; Moghadam LM; Yazdankhah M; Naji M; Salehi Z J Clin Neurosci; 2009 Oct; 16(10):1334-7. PubMed ID: 19581095 [TBL] [Abstract][Full Text] [Related]
33. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects. Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209 [TBL] [Abstract][Full Text] [Related]
34. Age-dependent decline in the apolipoprotein E level in cerebrospinal fluid from control subjects and its increase in cerebrospinal fluid from patients with Alzheimer's disease. Fukuyama R; Mizuno T; Mori S; Yanagisawa K; Nakajima K; Fushiki S Eur Neurol; 2000; 43(3):161-9. PubMed ID: 10765057 [TBL] [Abstract][Full Text] [Related]
35. Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Bibl M; Esselmann H; Otto M; Lewczuk P; Cepek L; Rüther E; Kornhuber J; Wiltfang J Electrophoresis; 2004 Sep; 25(17):2912-8. PubMed ID: 15349929 [TBL] [Abstract][Full Text] [Related]
36. CSF evidence of pericyte damage in Alzheimer's disease is associated with markers of blood-brain barrier dysfunction and disease pathology. Miners JS; Kehoe PG; Love S; Zetterberg H; Blennow K Alzheimers Res Ther; 2019 Sep; 11(1):81. PubMed ID: 31521199 [TBL] [Abstract][Full Text] [Related]
37. Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. Chakraborty A; Chatterjee M; Twaalfhoven H; Del Campo Milan M; Teunissen CE; Scheltens P; Fontijn RD; van Der Flier WM; de Vries HE Alzheimers Res Ther; 2018 Jun; 10(1):58. PubMed ID: 29933741 [TBL] [Abstract][Full Text] [Related]
38. Detection of amyloid beta protein precursor immunoreactivity in normal and Alzheimer's disease cerebrospinal fluid. Chong JK; Miller BE; Ghanbari HA Life Sci; 1990; 47(13):1163-71. PubMed ID: 2122149 [TBL] [Abstract][Full Text] [Related]